Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from RAPT rapeutics

RAPT Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, RAPT Therapeutics (NASDAQ:RAPT) reported Q1 sales of $641.00 thousand. Earnings fell to a loss of $20.47 million, resulting in a 14.16% decrease from last quarter.

Benzinga · Jun 15, 2022

What 4 Analyst Ratings Have To Say About RAPT Therapeutics

What 4 Analyst Ratings Have To Say About RAPT Therapeutics

Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter:

Benzinga · May 24, 2022

Starbucks And 2 Other Stocks Insiders Are Buying

Starbucks And 2 Other Stocks Insiders Are Buying

Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades.

Benzinga · May 13, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: RAPT Therapeutics Q1 Earnings

RAPT Therapeutics (NASDAQ:RAPT) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 11, 2022

RAPT Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but RAPT Therapeutics still reported an overall loss of $17.93 million.

Benzinga · Mar 14, 2022

1

Coverage From

Benzinga

Organisations

Occidental Petroleum

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play